Endothelial and inflammatory pathophysiology in dengue shock: New insights from a prospective cohort study in Vietnam
Angela McBride,Huynh Thi Le Duyen,Nguyen Lam Vuong,Phan Vinh Tho,Luong Thi Hue Tai,Nguyen Thanh Phong,Nguyen Thanh Ngoc,Lam Minh Yen,Phung Tran Huy Nhat,Tran Thuy,Martin J. Llewelyn,Louise Thwaites,Nguyen Van Hao,Sophie Yacoub,Tran Thuy Vi
DOI: https://doi.org/10.1371/journal.pntd.0012071
2024-03-28
PLoS Neglected Tropical Diseases
Abstract:Dengue shock (DS) is the most severe complication of dengue infection; endothelial hyperpermeability leads to profound plasma leakage, hypovolaemia and extravascular fluid accumulation. At present, the only treatment is supportive with intravenous fluid, but targeted endothelial stabilising therapies and host immune modulators are needed. With the aim of prioritising potential therapeutics, we conducted a prospective observational study of adults (≥16 years) with DS in Vietnam from 2019–2022, comparing the pathophysiology underlying circulatory failure with patients with septic shock (SS), and investigating the association of biomarkers with clinical severity (SOFA score, ICU admission, mortality) and pulmonary vascular leak (daily lung ultrasound for interstitial and pleural fluid). Plasma was collected at enrolment, 48 hours later and hospital discharge. We measured biomarkers of inflammation (IL-6, ferritin), endothelial activation (Ang-1, Ang-2, sTie-2, VCAM-1) and endothelial glycocalyx breakdown (hyaluronan, heparan sulfate, endocan, syndecan-1). We enrolled 135 patients with DS (median age 26, median SOFA score 7, 34 required ICU admission, 5 deaths), together with 37 patients with SS and 25 healthy controls. Within the DS group, IL-6 and ferritin were associated with admission SOFA score (IL-6: βeta0.70, p<0.001 & ferritin: βeta0.45, p<0.001), ICU admission (IL-6: OR 2.6, p<0.001 & ferritin: OR 1.55, p<0.001) and mortality (IL-6: OR 4.49, p = 0.005 & ferritin: OR 13.8, p = 0.02); both biomarkers discriminated survivors and non-survivors at 48 hours and all patients who died from DS had pre-mortem ferritin ≥100,000ng/ml. IL-6 most strongly correlated with severity of pulmonary vascular leakage (R = 0.41, p<0.001). Ang-2 correlated with pulmonary vascular leak (R = 0.33, p<0.001) and associated with SOFA score (β 0.81, p<0.001) and mortality (OR 8.06, p = 0.002). Ang-1 was associated with ICU admission (OR 1.6, p = 0.005) and mortality (OR 3.62, p = 0.006). All 4 glycocalyx biomarkers were positively associated with SOFA score, but only syndecan-1 was associated with ICU admission (OR 2.02, p<0.001) and mortality (OR 6.51, p<0.001). This study highlights the central role of hyperinflammation in determining outcomes from DS; the data suggest that anti-IL-1 and anti-IL-6 immune modulators and Tie2 agonists may be considered as candidates for therapeutic trials in severe dengue. Dengue is the most common arboviral infection worldwide. Dengue shock is the most severe complication of dengue infection; patients develop marked plasma leakage, hypovolaemia and extravascular fluid accumulation. At present, the only treatment available is intravenous fluid, but targeted therapies are needed. With the aim of prioritizing potential therapeutics, we conducted a prospective observational study of 135 adults with dengue shock in Vietnam, investigating the association between biomarkers of inflammation, endothelial activation and endothelial glycocalyx breakdown and clinical severity, and comparing pathophysiology with patients with septic shock and healthy controls. In the dengue shock group, 5/135 patients died. The inflammatory biomarkers IL-6 and ferritin were associated with SOFA score, requirement for ICU admission and mortality. IL-6 most strongly correlated with severity of vascular leakage in the lung, measured by ultrasound. The endothelial biomarkers Angiopoietin-2 and syndecan-1 were both also associated with SOFA score and mortality. Our findings highlight the central role of hyperinflammation in determining outcomes from dengue shock; the data suggest that anti-IL-1 and anti-IL-6 immune modulators and Tie2 agonists may be considered as candidates for therapeutic trials in severe dengue.
tropical medicine,parasitology